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Background: The debilitating nature of migraine and challenges associated with treatment-refractory migraine
have a profound impact on patients. With the need for alternatives to pharmacologic agents, vagus nerve
stimulation has demonstrated efficacy in treatment-refractory primary headache disorders. We investigated the use
of cervical non-invasive vagus nerve stimulation (nVNS) for the acute treatment and prevention of migraine attacks
in treatment-refractory episodic and chronic migraine (EM and CM) and evaluated the impact of nVNS on migraine-
associated sleep disturbance, disability, and depressive symptoms.
Methods: Twenty patients with treatment-refractory migraine were enrolled in this 3-month, open-label,
prospective observational study. Patients administered nVNS prophylactically twice daily at prespecified times and
acutely as adjunctive therapy for migraine attacks. The following parameters were evaluated: pain intensity (visual
analogue scale [VAS]); number of headache days per month and number of migraine attacks per month; number of
acutely treated attacks; sleep quality (Pittsburgh Sleep Quality Index [PSQI]); migraine disability assessment (MIDAS);
depressive symptoms (Beck Depression Inventory® [BDI]); and adverse events (AEs).
Results: Of the 20 enrolled patients, 10 patients each had been diagnosed with EM and CM. Prophylaxis with nVNS was
associated with significant overall reductions in patient-perceived pain intensity; median (interquartile range) VAS scores at
baseline versus 3 months were 8.0 (7.5, 8.0) versus 4.0 (3.5, 5.0) points (p < 0.001). Baseline versus 3-month values (mean ±
standard error of the mean) were 14.7 ± 0.9 versus 8.9 ± 0.8 (p < 0.001) for the number of headache days per month and
7.3 ± 0.9 versus 4.5 ± 0.6 (p < 0.001) for the number of attacks per month. Significant improvements were also noted in
MIDAS (p < 0.001), BDI (p < 0.001), and PSQI global (p< 0.001) scores. No severe or serious AEs occurred.
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Conclusion: In this study, treatment with nVNS was safe and provided clinically meaningful decreases in the frequency
and intensity of migraine attacks in patients with treatment-refractory migraine. Improvements in migraine-associated
disability, depression, and sleep quality were also noted.
Keywords: Neuromodulation, Headache, Acute therapy, Prophylactic therapy, Sleep impairmentBackground
As a highly prevalent neurologic disorder, migraine
headache exerts a considerable burden on individuals
and society [1, 2], including substantial economic costs
[3]. Recent findings from the Global Burden of Disease
Study 2013 suggest that migraine ranks sixth among the
top worldwide causes of disability [4, 5]. Along with
premonitory (i.e. aura) and attack-associated symptoms
(i.e. phonophobia, photophobia, nausea, and vomiting)
[2], patients with migraine are likely to experience sleep
disturbances [6, 7] and other comorbidities such as
depression and anxiety [8, 9]. Sleep disturbances may
trigger a migraine attack in the preictal state [6]. Patients
with non-sleep migraine (NSM) demonstrate low
thermal pain thresholds, whereas insufficient rest may
evoke migraine attacks in patients with sleep migraine
(SM) [6, 10].
Although there is no clear consensus on precisely how
to define refractory migraine, a key parameter among
commonly used clinical definitions is unresponsiveness
to medications from multiple pharmacologic classes
[11]. Thus, individuals with treatment-refractory
migraine require alternatives to standard pharmacologic
therapies. Neuromodulation therapy using implanted
vagus nerve stimulation (VNS) devices has been success-
fully used to treat drug-resistant epilepsy [12] and
depression [13], and numerous other methods of neuro-
modulation (e.g. occipital nerve stimulation, non-
invasive VNS, transcranial direct current stimulation,
repetitive transcranial magnetic stimulation, transcuta-
neous electrical nerve stimulation, transcutaneous
supraorbital nerve stimulation, spinal cord stimulation)
have been investigated for treating patients with
migraine, with varying degrees of success [14]. Small
studies and case reports have shown that implanted
VNS may also alleviate migraine and cluster headache
[15–18]. Data suggest that attenuation of pain by VNS
occurs via inhibition of signalling through afferent vagus
nerve fibres to the trigeminal nucleus caudalis (TNC)
[19] and via modulation of inhibitory neurotransmitter
release, resulting in decreased glutamate levels in the
TNC [20, 21].
The use of implanted VNS devices for the treatment
of headache disorders is hampered by inherent proc-
edural risks (i.e. infection, lead migration, lead fracture,and battery replacement), health complications (i.e. voice
disturbance, cough, headache, and paraesthesia), surgery
cost, and the need for postoperative monitoring [22, 23].
Thus, a non-invasive vagus nerve stimulation (nVNS)
device (gammaCore®; electroCore, LLC) has been devel-
oped and is CE-marked for the treatment of primary
headache disorders [24]. Recent evidence suggests that
nVNS is effective in the acute treatment of migraine [25,
26] and in the acute or prophylactic treatment of cluster
headache [27–29]. An open-label pilot study that evalu-
ated nVNS for the acute treatment of episodic migraine
(EM) attacks reported that the efficacy of nVNS at 2 h
after initiation of therapy was comparable to that of
first-line pharmacologic interventions [25]. Barbanti and
colleagues evaluated the use of nVNS for the acute treat-
ment of migraine attacks in patients with chronic mi-
graine (CM) and high-frequency EM [26]. The majority
of patients with mild or moderate migraine attacks
achieved pain relief or pain-free status at both 1 and 2 h
after nVNS treatment [26].
No published studies to date have examined the effect
of nVNS on sleep quality and depression in patients with
migraine. We therefore conducted a 3-month, open-
label, prospective, observational cohort study to investi-
gate the safety and efficacy of acute and prophylactic
nVNS treatment in patients with EM and CM and assess
the effects of nVNS on sleep quality in these patients.
Methods
Study design
This was a 3-month, single-centre, open-label, prospec-
tive, observational cohort study to evaluate the impact
of preventive and acute treatment with nVNS in patients
with treatment-refractory EM and CM and migraine-
associated sleep disturbances, disability, and depressive
symptoms. Patients were referred to our department by
a headache specialist (neurologist), and their diagnoses
were confirmed by a multidisciplinary pain board con-
sisting of neurologists, anaesthesiologists, neurosur-
geons, psychiatrists, and pain nurses.
Ethics, consent, and permissions
Approval for this study was obtained from the institu-
tional ethics committee. All patients provided written in-
formed consent.
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Patients who were diagnosed with EM (headaches
occurring <15 days per month) or CM (headaches
occurring ≥15 days per month) according to the
International Classification of Headache Disorders
criteria (3rd edition; beta version) [2] and who
fulfilled all of the inclusion criteria and none of the
exclusion criteria (Table 1) were enrolled. All pa-
tients enrolled in the study were considered refrac-
tory to prophylactic treatment having previously
failed 4 or more classes of medications (i.e. beta [β]-
blocker, anticonvulsant, tricyclic antidepressant, and
calcium channel blocker) and behavioural therapy.Stimulation paradigm
The nVNS device (provided by electroCore, LLC,
Basking Ridge, NJ, USA) is a handheld, portable ap-
pliance that employs a constant voltage-driven signal
consisting of a 1-millisecond burst of 5-kHz sine
waves repeated at a frequency of 25 Hz, with stimu-
lation intensity ranging from 0 to 24 V. The device
is positioned against the side of the neck below the
mandibular angle, medial to the sternocleidomastoid
muscle and lateral to the larynx. Stimulations are de-
livered transcutaneously in the region of the cervical
branch of the vagus nerve through 2 stainless steel
disc electrodes that are manually coated with a con-
ductive gel.
For prophylactic therapy, patients were instructed
to administer two 2-min stimulations of nVNS
(1 stimulation on each side of the neck in the
regions of the right and left cervical vagus nerves)
twice daily (morning and late afternoon; total of 4
doses per day) (Fig. 1). For acute therapy, patients
were advised to administer two 2-min stimulations
(1 stimulation on each side of the neck) at the time
of acute medication intake. Before study commence-
ment, all patients received training from the same
instructor regarding how to use the device.Table 1 Inclusion and exclusion criteria
Inclusion criteria
• Chronic refractory headache disorder according to ICHD-3 beta criteria
• Age ≥18 years
• Migraine attacks that are refractory to medical or behavioural therapy
• Eligible for nVNS therapy
• Willingness to comply with a defined follow-up interval
• Intracranial and cervical pathologies ruled out by an MRI scan
• Stable pain medication for 4 weeks prior to nVNS
Abbreviations: ICHD-3 International Classification of Headache Disorders (3rd edition), MRAssessments and end points
Data for all efficacy and safety outcomes were ob-
tained from patient-completed headache diaries and
by physician questioning during outpatient visits. Effi-
cacy related to prophylactic therapy was assessed by
evaluating the change from baseline in patient-
reported pain intensity, number of headache days per
month, and number of migraine attacks per month.
Baseline values for the number of headache days per
month and number of migraine attacks per month
were determined on the basis of patient reporting and
medical history. The efficacy of acute nVNS treatment
on individual attacks was assessed using subjective
patient reports of overall pain relief or pain freedom
as self-reported at baseline and after 3 months of
therapy. Data for all reported and treated attacks were
pooled and analysed. The onset, severity, and frequency
of treatment-related adverse events (AEs) were evalu-
ated. Furthermore, impaired sleep quality (Pittsburgh
Sleep Quality Index [PSQI] score) [30], depressive symp-
toms (Beck Depression Inventory® [BDI; Psychological
Corporation of San Antonio, San Antonio, TX, USA]
score) [31], and migraine disability (Migraine Disability
Assessment [MIDAS]) scores and grades [32] were evalu-
ated at baseline and after 3 months of nVNS treatment.
Sleep disturbances were classified according to the onset
of the migraine attack (SM vs NSM) and in relation to
the time of sleep evaluation (interictal: 48 h from last
attack; or preictal or postictal: <48 h from last attack)
(Table 3).
Statistical analysis
Univariate analyses of data obtained at baseline and after
3 months of nVNS treatment were performed to deter-
mine changes in pain intensity (visual analogue scale
[VAS] score), headache days/month, MIDAS score/grade,
number of migraine attacks per month, and depressive
(BDI) and sleep (PSQI) comorbidities. Comparisons of the
outcomes at baseline and 3 months’ follow-up were per-
formed using the McNemar test for binominal variablesExclusion criteria
• Other concomitant neuropsychiatric comorbidity that is not adequately
classified or requires a specific diagnosis or treatment
• Pregnancy
• Previous invasive or non-invasive neuromodulation therapy or ablative
procedure
• Unwillingness to complete pain diary and provide information on pain
intensity and migraine attack frequency (i.e. number of migraine attacks
per month)
• Cerebrovascular or cardiovascular disease
I magnetic resonance imaging, nVNS non-invasive vagus nerve stimulation
Fig. 1 Non-invasive vagus nerve stimulation device
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appropriate, for continuous data. P-values <0.05 were
considered significant. All patients were included in the
analyses; subgroup analyses were performed for patients
with EM and CM. Statistical analyses were performed in-
dependently by North American Science Associates Inc.
(Minneapolis, MN, USA) using SAS® 9.2 (SAS Institute
Inc., Cary, NC, USA).Results
Demographic and baseline characteristics
Of the 20 participants, 16 were female and 4 were male,
with an average age of 53.1 years (range, 35–72 years).
Ten patients each had been diagnosed with EM (9 with-
out aura/1 with aura) and CM (8 without aura/2 with
aura). All patients were classified as MIDAS grade III/IV,
with most having clinical signs of sleep disturbance
(average PSQI score, 8.3 points; range, 2–17 points) and
depressive symptoms (average BDI score, 17.3 points;
range, 5–34 points) (Table 2). Evaluation of sleep
patterns at baseline revealed that of 20 patients, 15
(6 EM/9 CM) had a disturbed sleep architecture (i.e. glo-
bal PSQI score of >5 points), and most patients (18/20)
had NSM (Table 3). The majority of patients (18/20) had
body mass index (BMI) values ≤30 kg/m2; 2 patients
(1 EM/1 CM) had BMI values >30 kg/m2.Preventive use of nVNS
Median (interquartile range [IQR]) pain intensity (VAS
score) in the total study population was 8 (7.5, 8.0)
points at baseline and significantly declined to 4 (3.5, 5)
points after 3 months of nVNS use (p < 0.001) (Fig. 2).
Reductions in pain intensity were observed in both EM
(baseline vs 3 months of nVNS treatment: 8 [7, 8] vs 3.5
[3, 4] points; p = 0.002) and CM (8 [8, 8] vs 5 [4, 5]
points; p = 0.002) subgroups (Fig. 2). The overall mean ±
standard error of the mean (SEM) number of headache
days per month declined from 14.7 ± 0.9 to 8.9 ± 0.8 days
(p < 0.001) (Fig. 3). Similarly, the number of headache
days declined in both the EM (11.3 ± 0.6 vs 5.7 ± 0.5 days;
p < 0.001) and CM (18.1 ± 0.8 vs 12.1 ± 0.6 days;
p < 0.001) subgroups (Fig. 3). The number of migraine
attacks per month declined significantly in the total
population (7.3 ± 0.9 vs 4.5 ± 0.6 attacks; p < 0.001), the
EM subgroup (4.9 ± 0.6 vs 3.0 ± 0.4 attacks; p = 0.02),
and the CM subgroup (9.7 ± 1.2 vs 5.9 ± 0.8 attacks;
p < 0.001) (Fig. 4).Acute treatment with nVNS
All patients reported that they had treated each of
their migraine attacks with adjunctive nVNS during
the 3-month treatment phase. Overall, patients with
EM treated 90 migraine attacks with nVNS, and
patients with CM treated 177 migraine attacks with
the device. All patients self-reported at least some
overall pain relief with their pre-existing acute treat-
ment at baseline and with adjunctive acute nVNS use
at follow-up. Of the 9 patients who reported a
maximum benefit of pain relief at baseline, 5 (2 EM/
3 CM) were able to achieve pain freedom within 2 h
after initiating adjunctive nVNS treatment as reported
at 3 months (p = 0.03).

































1 f 36 EM+ 6 6 10 III (18) 18 4 Classes + Mg
+ Botox®
Triptan + 60 min 24 5
2 f 66 CM- 6 8 20 IV (45) 19 4 Classes +
Botox
NSAID + 90 min 23 12
3 f 41 CM- 7 8 20 IV (39) 34 4 Classes Triptan + 60 min 31 12
4 m 70 CM- 7 7 15 IV (39) 15 Calcium
channel
blocker
NSAID + 45 min 25 2
5 f 56 CM+ 17 8 18 IV (51) 17 N/A Triptan + 60 min 25 17
6 f 60 CM- 8 8 22 IV (44) 16 4 Classes +
Botox
Triptan + 60 min 24 7
7 f 35 EM- 4 8 9 III (19) 8 4 Classes +
Botox
Triptan + 60 min 17 8
8 m 50 EM- 5 7 9 IV (37) 23 4 Classes +
Botox
NSAID + 160 min 40 6
9 f 50 EM- 3 9 9 IV (45) 5 4 Classes +
Botox
Triptan + 30 min 22 7
10 f 35 CM- 12 8 15 IV (36) 11 4 Classes +
Botox
Triptan + 60 min 22 12
11 m 39 EM- 4 8 12 III (19) 21 Calcium
channel
blocker + Mg +
Ca++
NSAID + 150 min 29 7
12 f 52 EM- 4 8 12 III (19) 21 4 Classes + Mg Triptan + 150 min 23 3
13 f 45 CM- 15 8 18 IV (33) 25 4 Classes +
Botox
NSAID + 45 min 23 17
14 f 54 EM- 4 8 12 III (18) 17 4 Classes + Mg Triptan + 120 min 25 4
15 f 60 EM- 10 8 14 III (19) 18 4 Classes + Mg Triptan + 60 min 18 5
16 f 60 EM- 5 7 14 III (16) 16 4 Classes +
Botox
Triptan + 120 min 20 11
17 f 59 CM+ 10 8 15 III (18) 16 4 Classes +
Botox
Triptan + 90 min 22 6
18 m 72 CM- 9 8 18 III (17) 15 4 Classes NSAID + 90 min 22 8
19 f 60 CM- 6 8 20 IV (44) 16 4 Classes +
Botox
Triptan + 60 min 24 6
20 f 62 EM- 4 7 12 III (16) 15 4 Classes +
Botox
Triptan + 120 min 20 10
Abbreviations: BDI Beck Depression Inventory, BMI body mass index, Ca++ calcium, CM chronic migraine, EM episodic migraine, f/m female/male, Mg magnesium,
MIDAS Migraine Disability Assessment, NSAID nonsteroidal anti-inflammatory drug, PSQI Pittsburgh Sleep Quality Index, VAS visual analogue scale, 4 Classes β-
blocker, anticonvulsant, tricyclic antidepressant, calcium channel blocker, −/+ without aura/with aura
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In the total population, significant reductions were ob-
served in the median (IQR) MIDAS score (baseline vs
3 months of nVNS treatment: 26 [18, 41.5] vs 15 [9,
34.5] points; p < 0.001) and MIDAS grade (3.5 [3, 4] vs 3
[2, 4]; p = 0.008) (Fig. 5a). A significant decrease in the
MIDAS score was also observed in the CM subgroup
(39 [33, 44] vs 16 [9, 36] points; p = 0.002) but not in the
EM subgroup (Fig. 5a).A significant reduction from baseline to 3 months in the
mean ± SEM BDI score was noted in the total population
(17.3 ± 1.4 vs 10.8 ± 1.1 points; p < 0.001), the EM subgroup
(16.2 ± 1.8 vs 8.4 ± 0.9 points; p < 0.001), and the CM sub-
group (18.4 ± 2.1 vs 13.2 ± 1.6 points; p < 0.001) (Fig. 5b).
Similarly, significant reductions in the global PSQI
score were observed in the total population (7 [5.5,
11.5] vs 5 [5, 8.5] points; p < 0.001), the EM sub-
group (6.5 [5, 8] vs 5 [5, 5] points; p = 0.03), and the
Table 3 Distribution of sleep patterns
Patient No. Sex Age, years Migraine Type Migraine Attack Onset Sleep Evaluation BMI, kg/m2 Global PSQI Score
1 f 36 EM+ NSM IC 24 5
2 f 66 CM- NSM IC 23 12
3 f 41 CM- NSM IC 31 12
4 m 70 CM- NSM IC 25 2
5 f 56 CM+ NSM PC 25 17
6 f 60 CM- NSM PC 24 7
7 f 35 EM- NSM IC 17 8
8 m 50 EM- NSM IC 40 6
9 f 50 EM- NSM IC 22 7
10 f 35 CM- NSM IC 22 12
11 m 39 EM- NSM IC 29 7
12 f 52 EM- SM IC 23 3
13 f 45 CM- NSM IC 23 17
14 f 54 EM- NSM IC 25 4
15 f 60 EM- NSM IC 18 5
16 f 60 EM- NSM IC 20 11
17 f 59 CM+ NSM IC 22 6
18 m 72 CM- NSM IC 22 8
19 f 60 CM- SM IC 24 6
20 f 62 EM- NSM PC 20 10
Abbreviations: BMI body mass index, CM chronic migraine, EM episodic migraine, f/m female/male, IC interictal, NSM non-sleep migraine, PC preictal or postictal,
PSQI Pittsburgh Sleep Quality Index, SM sleep migraine, −/+without aura/with aura
Fig. 2 Pain intensity (median [IQR]). Abbreviations: CM chronic migraine, EM episodic migraine, IQR interquartile range, nVNS non-invasive vagus nerve
stimulation, VAS visual analogue scale. Pain intensity (VAS) scores at baseline (blue bars) and after 3 months of treatment with nVNS
(orange bars) in all patients, patients with EM, and patients with CM. Data are shown as median (IQR); whiskers indicate the minimum
and maximum values
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Fig. 3 Number of headache days per month (mean ± SEM). Abbreviations: CM chronic migraine, EM episodic migraine, nVNS non-invasive vagus
nerve stimulation, SEM standard error of the mean. Number of headache days per month at baseline (blue bars) and after 3 months of treatment
with nVNS (orange bars) in all patients, patients with EM, and patients with CM. Baseline measures were determined on the basis of patient
reporting and medical history. Data are shown as mean ± SEM
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p = 0.02) (Fig. 5c and Table 4). Reductions in PSQI
subscores were significant in the total population for
latency (1 [0.5, 3.5] vs 1 [0.5, 2] point; p = 0.03) and
daytime dysfunction (2.5 [2, 4] vs 2 [1, 2] points;
p = 0.004) (Table 4). Trends toward lower PSQI sub-
scores after treatment were observed for daytime
dysfunction in the EM subgroup (2.5 [2, 4] vs 2
[1, 2] points; p = 0.06) and for latency in the CM
subgroup (2.5 [1, 5] vs 2 [1, 3] points; p = 0.06).Fig. 4 Number of migraine attacks per month (mean ± SEM). Abbreviations: C
nerve stimulation, SEM standard error of the mean. The number of migraine a
with nVNS (orange bars) in all patients, patients with EM, and patients with CM
and medical history. Data are shown as mean ± SEMIncidence of AEs
Four patients reported mild treatment-related AEs, most
commonly neck twitching and skin irritation. These AEs
were transient, coincided with the period of stimulation,
and resolved during the course of treatment. No severe
or serious AEs occurred.
Discussion
In this study, a clinically meaningful response to
3 months of prophylactic nVNS therapy was observedM chronic migraine, EM episodic migraine, nVNS non-invasive vagus
ttacks per month at baseline (blue bars) and after 3 months of treatment
. Baseline measures were determined on the basis of patient reporting
Fig. 5 Migraine disability and migraine-associated comorbidities. Abbreviations: BDI Beck Depression Inventory, CM chronic migraine, EM episodic
migraine, IQR interquartile range, MIDAS Migraine Disability Assessment, nVNS non-invasive vagus nerve stimulation, PSQI Pittsburgh Sleep Quality
Index, SEM standard error of the mean. MIDAS (a), BDI (b), and PSQI (c) scores at baseline (blue bars) and after 3 months of nVNS treatment (orange
bars) in all patients, patients with EM, and patients with CM. Data are shown as median (IQR) for MIDAS and PSQI (whiskers indicate the minimum
and maximum values) and as mean ± SEM for BDI
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subgroups (EM and CM), and nVNS was associated
with significant reductions in pain intensity and num-
ber of headache days per month. A significant de-
crease in the number of migraine attacks per monthwas noted in the total population and in both sub-
groups. After 3 months, MIDAS scores and MIDAS
grades significantly decreased in the total population.
Significant improvements in BDI and PSQI scores
were observed for the total population and for both
Table 4 Pittsburgh Sleep Quality Index (PSQI) scores
Baseline Post nVNS P-value
PSQI global score 7 (5.5, 11.5) 5 (5, 8.5) <0.001
PSQI subscores
Subjective sleep quality 1 (1, 1) 1 (1, 1) 0.25
Sleep latency 1 (0.5, 3.5) 1 (0.5, 2) 0.03
Sleep duration 0 (0, 0) 0 (0, 0) N/A
Sleep efficacy 0 (0, 0.5) 0 (0, 0.5) N/A
Sleep disturbance 2 (1, 2) 1 (1, 2) 0.13
Sleep medication 0 (0, 1) 0 (0, 0.5) 0.13
Daytime dysfunction 2.5 (2, 4) 2 (1, 2) 0.004
Abbreviations: IQR interquartile range, N/A not applicable, nVNS non-invasive
vagus nerve stimulation
Data are presented as median (IQR)
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with no serious or severe treatment-related AEs.
Migraine is associated with a considerable economic
burden [3], and findings from the International Burden
of Migraine Study [33] suggest that therapies aimed at
decreasing headache frequency and/or headache-related
disability are important in containing costs and reducing
the clinical and economic strain of migraine. The signifi-
cant decreases in the number of headache attacks per
month and MIDAS scores that were noted in the
current study suggest that nVNS may have substantial
utility in this regard.
The limitations of the current study include its open-
label design, lack of control arm and prospective run-in
period, self-recollected reporting of acute pain relief and
pain freedom findings, and its small patient population.
The lack of a control arm did not allow for examination
of the placebo effect, which has been noted consistently
in studies of migraine interventions [25, 34]. The
method used for reporting acute pain relief and pain
freedom was based on patients’ general impressions and
did not involve the use of a validated pain scale.
To date, 2 studies have investigated prophylactic therapy
for migraine using non-invasive neuromodulation devices
[35, 36]. Findings from the current study are consistent with
those reported in a study of prophylactic therapy for CM
using non-invasive transcutaneous auricular VNS [35] and
those reported in a study of prophylactic therapy for mi-
graine using non-invasive transcutaneous supraorbital
stimulation [36]. However, unlike the current study, the
aforementioned studies did not evaluate the effect of
prophylactic nVNS therapy in both EM and CM subgroups.
This study was the first to examine the effect of nVNS
on sleep quality in patients with migraine. Significant
improvements in sleep quality after 3 months of treat-
ment with nVNS were observed; however, further stud-
ies are required to validate these findings. Results from
the current study also confirmed the favourable safetyprofile of nVNS that was reported in previous studies of
nVNS in the treatment of migraine [25, 26]. As first-line
pharmacologic therapy for the acute treatment of mi-
graine, triptans (i.e. serotonin 5-HT1B/1D agonists) are
associated with a risk for cardiovascular/cerebrovascular
side effects [37–39]. Thus, nVNS may serve as a safe al-
ternative to triptans, which may potentially lower the
risk for medication-overuse headache [40].
The therapeutic effects of nVNS reported in the current
study are supported by findings from human neuroimag-
ing studies and from animal studies of migraine pain and
cortical spreading depression (CSD) [21, 41–43]. Func-
tional magnetic resonance imaging studies in patients with
migraine reflect heightened sensory facilitation, decreased
inhibition in response to sensory stimuli, and lack of or
decreased adaptation to interictal stimuli [44]. Neuroim-
aging studies of VNS demonstrate thalamic involvement,
which is responsible for processing somatosensory infor-
mation and regulating cortical activity [41]. Thus, in pa-
tients with migraine, nVNS therapy may help to
counteract the decline in thalamocortical activity that is
responsible for the decreased habituation to interictal
stimuli [45]. The potential role of nVNS in migraine-
associated pain and CSD has been investigated in animal
studies [21, 42, 43]. In a rat model of trigeminal allodynia,
Oshinsky and colleagues demonstrated that nVNS de-
creased trigeminal nociceptive stimulation by inhibiting
nitric oxide–induced increases in glutamate levels in the
TNC [21]. Further evaluation of the analgesic effect of
VNS suggests that VNS inhibits the increase in c-fos ex-
pression in the TNC that occurs in response to painful
stimuli [43]. With regard to migraine aura, which is be-
lieved to result from CSD [46], Chen and colleagues com-
pared the effect of direct VNS using implanted VNS with
the effect of nVNS in a rat model of CSD [42]. Compared
with control treatment, both modes of VNS suppressed
CSD susceptibility, with nVNS being more effective than
direct VNS [42].
Evidence suggests that the degree of response to nVNS
may vary depending on the side of stimulation [47].
Examination of cervical vagus nerve morphology at the
site of electrode implantation shows that the right vagus
nerve has a considerably larger surface area and more
tyrosine hydroxylase–positive nerve fibres than the left
vagus nerve, which may be relevant with respect to the
side of stimulation [47]. Stimulation-mediated sympa-
thetic- and catecholamine-driven effects and variations
in the amount of epineurial connective tissue may modu-
late treatment response [47]. In the current study,
patients administered treatment to both the right and
left vagus nerves. However, in 3 recently published stud-
ies of nVNS for migraine and cluster headache, stimula-
tion in the region of the right vagus nerve was
implemented [25, 26, 29].
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In conclusion, this study demonstrated that administra-
tion of nVNS therapy in patients with treatment-
refractory migraine was associated with significant
reductions in the monthly number of headache days, a
preferred outcome measure in migraine studies, and pain
intensity. In addition, there were clinically meaningful im-
provements in migraine-associated disability, depression,
and sleep quality. The role of nVNS in migraine therapy is
being further explored in ongoing large-scale, randomised,
sham-controlled trials with long-term follow-up.
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